Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced financial results for the fourth quarter and year ended December 31, 2012.
“After a period of transition in 2012, we are very encouraged by the company’s progress and our better than projected cash balance at the end of the year,” said John Nicols, President and CEO of Codexis.
“After a period of transition in 2012, we are very encouraged by the company’s progress and our better than projected cash balance at the end of the year,” said John Nicols, President and CEO of Codexis.
